LONDON – Clinical artificial intelligence (AI) specialist Sensyne Health plc agreed to a two-year collaboration with Bayer AG, in which it will apply its algorithms to analyze 3 million medical records, with the aim of identifying disease subtypes that support patient stratification in phase III trials in cardiovascular disease.